Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza Vaccine · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Influenza Vaccine | BIOLOGICAL | surface antigen, inactivated, prepared in cell cultures |
Inclusion Criteria 1. Female or male subjects \>= 18 years of age (adults \>= 18 to \< =60 years of age or elderly \>= 61 years of age). 2. Willing and able to give informed consent before any protocol procedures are performed. 3. Able to adhere to visit schedules and all protocol required study pr...
Influenza Vaccine is used for the prevention of influenza, commonly known as the flu. It is being developed as a vaccine to protect against seasonal influenza infection. The vaccine is intended for use in adults, including elderly populations, to reduce the risk of influenza and its complications.
Influenza Vaccine is being developed by Abbott Laboratories, a company traded on the stock exchange under the ticker symbol ABT. Abbott Laboratories is conducting clinical trials to evaluate the safety and immunogenicity of this vaccine for the prevention of influenza.
Influenza Vaccine is currently in Phase 3 clinical development. This phase involves large-scale studies to confirm the vaccine's efficacy and monitor adverse reactions. The most advanced trial, NCT00999206, is a Phase 3 study that has been completed, evaluating the safety, immunogenicity, and lot consistency of the cell-derived influenza vaccine.
Influenza Vaccine has been studied in two clinical trials. The first, NCT00999206, is a Phase 3 trial that has been completed, enrolling 3,138 participants in Australia and New Zealand to measure safety, immunogenicity, and lot consistency. The second, NCT01013675, is a Phase 2 trial completed with 622 elderly participants in Czechia, Estonia, and Lithuania, assessing immunogenicity and safety.
Yes, Influenza Vaccine is a cell-derived influenza vaccine. The clinical trials for this vaccine, including NCT00999206 and NCT01013675, specifically evaluate a cell-derived formulation. This means the vaccine is produced using cell culture technology rather than traditional egg-based methods, which may offer advantages in manufacturing speed and flexibility.